Business Wire

Positive New Data on Corcym’s Perceval Plus Sutureless Aortic Heart Valve Encompasses up to 7-Year Follow-up

9.10.2026 16:15:00 EEST | Business Wire | Press release

Share

Corcym, a global medical device company dedicated to cardiac surgery, today announced that positive mid-term data from a sub-analysis of its Perceval Plus sutureless aortic heart valve as part of its MANTRA clinical trial was featured in an oral presentation today at the annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS). The study is the longest follow-up available for Perceval Plus and the FREE tissue treatment from an international multicenter study, and demonstrated excellent durability, safety and quality of life improvements.

Perceval Plus is the only sutureless and collapsible aortic surgical heart valve. Its unique design performs in any surgical scenario and is optimal for endoscopy and robotics. The valve features the company’s FREE next generation tissue treatment addressing the two main causes of calcification, phospholipids and aldehydes. Its proprietary LANCELOT advanced manufacturing process includes zero-pressure shaping and laser cutting of the pericardium to optimize valve performance and consistency.

“This large study provides the longest clinical follow-up currently reported for the Perceval Plus valve and its FREE tissue technology, offering valuable insights into their sustained clinical and hemodynamic performance over time,” said lead author Michael Ibrahim, MD, PhD, at the University of Virginia Health University Medical Center. “These data demonstrate a favorable hemodynamic profile, characterized by durably low transvalvular gradients and minimal paravalvular regurgitation, along with low rates of reintervention and permanent pacemaker implantation. The high freedom from structural valve deterioration and valve-related reintervention observed during follow-up demonstrates an excellent mid-term durability profile.”

The study presented at EACTS is a sub-analysis including 708 patients treated with Perceval Plus in routine clinical practice at 45 centers as part of the company’s ongoing MANTRA study, a prospective multicenter international registry. The sub-analysis includes many patients reaching 7-year follow-up and is currently enrolling patients.

Highlights from the Perceval Plus sub-analysis include:

  • 99.7% freedom from structural valve deterioration (SVD) from 3 to 7 years
  • 96.6% freedom from aortic valve reoperation from 4 to 7 years
  • 3.7% permanent pacemaker implantation (PPI) rate at 30 days
  • Quality of life improvements:
    • 96.3% of patients classified as NYHA class I-II at 30 days (a 32% improvement from baseline), with more than 95% of patients sustaining that status at 3 year follow-up
    • 19% improvement in mean KCCQ-12 scores from baseline at 30 days (59.6 23.3 to 72.8 22.1), substantially increasing to 31% improvement from baseline at 1 year (59.6 23.3 to 85.4 17.6)
    • 11% improvement in mean EQ-5D-5L VAS scores from baseline at 30 days (65.2 20.2 to 72.7 17.3), increasing to 18% improvement from baseline at 1 year (65.2 20.2 to 79.3 14.8)

In addition to the oral presentation, Perceval Plus is featured in six e-Posters and a Mini-Access Multi-Procedure at EACTS. To view the complete schedule of Perceval Plus and Corcym presentations in the scientific program, click here.

Also at EACTS, Corcym is launching two new devices in its Memo portfolio: TriMemo and Memo 4D Curve, both of which recently celebrated FDA clearance and first-in-human procedures in the U.S. TriMemo is the first device capable of delivering true three-dimensional physiologic motion to the tricuspid valve, and the first tricuspid device to leverage proprietary Memo technology. Memo 4D Curve is a nitinol-based, semi-rigid mitral annuloplasty device with an open configuration, giving surgeons who prefer an open ring access to the three-dimensional motion preservation capability of the Memo platform.

Corcym is exhibiting at EACTS Booth #30 at the International Barcelona Convention Center (CCIB).

“Our commitment to the cardiac surgeon is absolute, and as the specialty evolves, we are leading the way in preparing surgeons to uplevel their skills in order to confidently move into MICS and robotic surgery,” said Christian Mazzi, Chief Executive Officer of Corcym.

“As the only sutureless, collapsible surgical aortic valve, Perceval Plus is at the core of this transition. We are surrounding our innovative product offerings with new technologies, such as the CRIMSON AI-assisted CT analysis platform for aortic valve replacement planning, and our Corcym Academy, focused on training the Surgeons of the Future, to ensure that cardiac surgery remains at the forefront in improving patient lives.”

About Corcym

Corcym is the only global medical device company dedicated to cardiac surgeons, providing the best solutions to help their patients fight structural heart disease. Founded on five decades of trusted partnerships with cardiac surgeons and a comprehensive portfolio of structural heart solutions, Corcym’s innovative technologies offer surgeons a wide range of repair and replacement options for both open-heart and minimally invasive cardiac surgery techniques. https://www.corcym.com/ .

High-resolution product images and additional materials are available upon request.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261009199827/en/

Contacts

MEDIA CONTACTS:

Agency:
Michelle McAdam, Chronic Communications, Inc.
M: 1 310 902 1274
michelle@chronic-comm.com

CORCYM:
Giorgia Cannizzaro, Global Product Specialist & Communications, CORCYM
M: +39 3420460615
giorgia.cannizzaro@corcym.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Spatial Announces Release 2027 1.0 with New Enhancements Across CAD Modeling, Interoperability, Data Preparation, and Meshing17.11.2026 21:10:00 EET | Press release

Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced the availability of its 2027 1.0 Release. This latest release introduces new capabilities and enhancements across Spatial's 3D ACIS Modeler, CGM Modeler, 3D InterOp, Data Prep and CSM/CVM product lines. Designed to improve efficiency, flexibility and robustness across CAD modeling, interoperability, data preparation and simulation workflows, the release delivers enhanced geometry processing, expanded modeling capabilities, improved CAD translation and advances in mesh generation for a better workflow coverage. 3D ACIS Modeler Enhanced Blending (Filleting) The 3D ACIS Modeler introduces support for asymmetric fixed-width blends with a conic cross-section, providing users with finer control over smooth transitions between edges. This enhancement builds on the symmetric fixed-width blend with a conic cross-section capabilit

Global EV Alliance Survey: EV Drivers Identify Myths and Misconceptions as the Biggest Barrier to Adoption17.11.2026 20:00:00 EET | Press release

Myths and misconceptions about electric cars, from battery lifespan and fire risk to grid collapse, are the biggest barrier to EV adoption, according to respondents to the annual Global EV Driver Survey. The 2026 survey draws on responses from more than 29,500 EV drivers across 34 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117539716/en/ MYTHS. Battery lifespan (72%), fire risk (58%) and grid collapse (45%) top the list of EV myths reported by respondents to the 2026 Global EV Driver Survey, which gathered responses from more than 29,500 EV drivers across 34 countries. “The EV transition is not just an infrastructure or affordability challenge. It is also an information challenge. Outdated information and misconceptions continue to influence decisions long after the technology has moved on,” says Ellen Hiep, from the Steering Committee of the Global EV Alliance (GEVA). Myths the greatest barrier Asked to ide

TreeFrog Therapeutics Appoints James Sterling as Chief Financial Officer17.11.2026 19:04:00 EET | Press release

TreeFrog Therapeutics, a biotechnology company developing scalable cell therapies built on its proprietary C-Stem™ technology, today announced the appointment of James Sterling as Chief Financial Officer, effective November 1, 2026. James joins TreeFrog’s executive leadership team and reports to Mark Rothera, President and Chief Executive Officer. He oversees finance, investor relations and corporate development as the company enters its next phase of growth. “I am delighted to welcome James to TreeFrog. James brings a valuable combination of biotech CFO and Wall Street experience that supports our ambitions to develop TreeFrog into a key enabling partner and drug developer in the regenerative medicines field,” said Mark Rothera, President and Chief Executive Officer of TreeFrog Therapeutics. James contributes deep experience in corporate finance, capital markets and strategic planning across therapeutics and diagnostics. Recently, he served as Chief Financial Officer of Bluebird Bio (

Visa Report: AI-Enabled Fraud and Third-Party Attacks Are Scaling Worldwide17.11.2026 17:40:00 EET | Press release

Fraud is becoming more automated, targeted and global as criminals use AI to exploit weak points across the payments ecosystem and target third-party providers that can provide access to multiple downstream payment organizations, according to the Visa (NYSE: V) Fall 2026 Biannual Threats Report released today during International Fraud Awareness Week. Developed by Visa Payment Ecosystem Risk and Control (PERC), the report examines threat activity observed between January and June 2026 and finds that AI is not creating entirely new categories of fraud. Instead, it is helping criminals that execute existing attacks faster, at greater scale, and with greater precision, while increasingly targeting third-party providers that can provide access to multiple downstream organizations at once. Although attack volumes increased in several areas, the report also found evidence that coordinated, network-level defenses are reducing the impact of these threats. “AI is changing the economics of fraud

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye